Cargando…

On the identification of potential novel therapeutic targets for spinocerebellar ataxia type 1 (SCA1) neurodegenerative disease using EvoPPI3

EvoPPI (http://evoppi.i3s.up.pt), a meta-database for protein-protein interactions (PPI), has been upgraded (EvoPPI3) to accept new types of data, namely, PPI from patients, cell lines, and animal models, as well as data from gene modifier experiments, for nine neurodegenerative polyglutamine (polyQ...

Descripción completa

Detalles Bibliográficos
Autores principales: Sousa, André, Rocha, Sara, Vieira, Jorge, Reboiro-Jato, Miguel, López-Fernández, Hugo, Vieira, Cristina P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561075/
https://www.ncbi.nlm.nih.gov/pubmed/36848492
http://dx.doi.org/10.1515/jib-2022-0056
_version_ 1785117845988835328
author Sousa, André
Rocha, Sara
Vieira, Jorge
Reboiro-Jato, Miguel
López-Fernández, Hugo
Vieira, Cristina P.
author_facet Sousa, André
Rocha, Sara
Vieira, Jorge
Reboiro-Jato, Miguel
López-Fernández, Hugo
Vieira, Cristina P.
author_sort Sousa, André
collection PubMed
description EvoPPI (http://evoppi.i3s.up.pt), a meta-database for protein-protein interactions (PPI), has been upgraded (EvoPPI3) to accept new types of data, namely, PPI from patients, cell lines, and animal models, as well as data from gene modifier experiments, for nine neurodegenerative polyglutamine (polyQ) diseases caused by an abnormal expansion of the polyQ tract. The integration of the different types of data allows users to easily compare them, as here shown for Ataxin-1, the polyQ protein involved in spinocerebellar ataxia type 1 (SCA1) disease. Using all available datasets and the data here obtained for Drosophila melanogaster wt and exp Ataxin-1 mutants (also available at EvoPPI3), we show that, in humans, the Ataxin-1 network is much larger than previously thought (380 interactors), with at least 909 interactors. The functional profiling of the newly identified interactors is similar to the ones already reported in the main PPI databases. 16 out of 909 interactors are putative novel SCA1 therapeutic targets, and all but one are already being studied in the context of this disease. The 16 proteins are mainly involved in binding and catalytic activity (mainly kinase activity), functional features already thought to be important in the SCA1 disease.
format Online
Article
Text
id pubmed-10561075
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher De Gruyter
record_format MEDLINE/PubMed
spelling pubmed-105610752023-10-10 On the identification of potential novel therapeutic targets for spinocerebellar ataxia type 1 (SCA1) neurodegenerative disease using EvoPPI3 Sousa, André Rocha, Sara Vieira, Jorge Reboiro-Jato, Miguel López-Fernández, Hugo Vieira, Cristina P. J Integr Bioinform Workshop EvoPPI (http://evoppi.i3s.up.pt), a meta-database for protein-protein interactions (PPI), has been upgraded (EvoPPI3) to accept new types of data, namely, PPI from patients, cell lines, and animal models, as well as data from gene modifier experiments, for nine neurodegenerative polyglutamine (polyQ) diseases caused by an abnormal expansion of the polyQ tract. The integration of the different types of data allows users to easily compare them, as here shown for Ataxin-1, the polyQ protein involved in spinocerebellar ataxia type 1 (SCA1) disease. Using all available datasets and the data here obtained for Drosophila melanogaster wt and exp Ataxin-1 mutants (also available at EvoPPI3), we show that, in humans, the Ataxin-1 network is much larger than previously thought (380 interactors), with at least 909 interactors. The functional profiling of the newly identified interactors is similar to the ones already reported in the main PPI databases. 16 out of 909 interactors are putative novel SCA1 therapeutic targets, and all but one are already being studied in the context of this disease. The 16 proteins are mainly involved in binding and catalytic activity (mainly kinase activity), functional features already thought to be important in the SCA1 disease. De Gruyter 2023-02-28 /pmc/articles/PMC10561075/ /pubmed/36848492 http://dx.doi.org/10.1515/jib-2022-0056 Text en © 2023 the author(s), published by De Gruyter, Berlin/Boston https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License.
spellingShingle Workshop
Sousa, André
Rocha, Sara
Vieira, Jorge
Reboiro-Jato, Miguel
López-Fernández, Hugo
Vieira, Cristina P.
On the identification of potential novel therapeutic targets for spinocerebellar ataxia type 1 (SCA1) neurodegenerative disease using EvoPPI3
title On the identification of potential novel therapeutic targets for spinocerebellar ataxia type 1 (SCA1) neurodegenerative disease using EvoPPI3
title_full On the identification of potential novel therapeutic targets for spinocerebellar ataxia type 1 (SCA1) neurodegenerative disease using EvoPPI3
title_fullStr On the identification of potential novel therapeutic targets for spinocerebellar ataxia type 1 (SCA1) neurodegenerative disease using EvoPPI3
title_full_unstemmed On the identification of potential novel therapeutic targets for spinocerebellar ataxia type 1 (SCA1) neurodegenerative disease using EvoPPI3
title_short On the identification of potential novel therapeutic targets for spinocerebellar ataxia type 1 (SCA1) neurodegenerative disease using EvoPPI3
title_sort on the identification of potential novel therapeutic targets for spinocerebellar ataxia type 1 (sca1) neurodegenerative disease using evoppi3
topic Workshop
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561075/
https://www.ncbi.nlm.nih.gov/pubmed/36848492
http://dx.doi.org/10.1515/jib-2022-0056
work_keys_str_mv AT sousaandre ontheidentificationofpotentialnoveltherapeutictargetsforspinocerebellarataxiatype1sca1neurodegenerativediseaseusingevoppi3
AT rochasara ontheidentificationofpotentialnoveltherapeutictargetsforspinocerebellarataxiatype1sca1neurodegenerativediseaseusingevoppi3
AT vieirajorge ontheidentificationofpotentialnoveltherapeutictargetsforspinocerebellarataxiatype1sca1neurodegenerativediseaseusingevoppi3
AT reboirojatomiguel ontheidentificationofpotentialnoveltherapeutictargetsforspinocerebellarataxiatype1sca1neurodegenerativediseaseusingevoppi3
AT lopezfernandezhugo ontheidentificationofpotentialnoveltherapeutictargetsforspinocerebellarataxiatype1sca1neurodegenerativediseaseusingevoppi3
AT vieiracristinap ontheidentificationofpotentialnoveltherapeutictargetsforspinocerebellarataxiatype1sca1neurodegenerativediseaseusingevoppi3